Nonetheless, it is important to note that our present study is the first detailing a systemic modification in host metabolism caused by metformin in cancer patients treated with targeted therapy (the anti-HER2 monoclonal antibody trastuzumab) in combination with chemotherapy (anthracycline/taxane). This evidence concerns the gene ERBB2 and cancer.